Works matching AU Appelbaum, Frederick R.

Results: 92
    1
    2
    3
    4
    5

    AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report.

    Published in:
    Biomarker Research, 2020, v. 8, n. 1, p. 1, doi. 10.1186/s40364-020-00208-1
    By:
    • Pogosova-Agadjanyan, Era L.;
    • Moseley, Anna;
    • Othus, Megan;
    • Appelbaum, Frederick R.;
    • Chauncey, Thomas R.;
    • Chen, I-Ming L.;
    • Erba, Harry P.;
    • Godwin, John E.;
    • Jenkins, Isaac C.;
    • Fang, Min;
    • Huynh, Mike;
    • Kopecky, Kenneth J.;
    • List, Alan F.;
    • Naru, Jasmine;
    • Radich, Jerald P.;
    • Stevens, Emily;
    • Willborg, Brooke E.;
    • Willman, Cheryl L.;
    • Wood, Brent L.;
    • Zhang, Qing
    Publication type:
    Article
    6
    7
    8
    9
    10

    Cell Signaling-Based Classifier Predicts Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia.

    Published in:
    PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0118485
    By:
    • Cesano, Alessandra;
    • Willman, Cheryl L.;
    • Kopecky, Kenneth J.;
    • Gayko, Urte;
    • Putta, Santosh;
    • Louie, Brent;
    • Westfall, Matt;
    • Purvis, Norman;
    • Spellmeyer, David C.;
    • Marimpietri, Carol;
    • Cohen, Aileen C.;
    • Hackett, James;
    • Shi, Jing;
    • Walker, Michael G.;
    • Sun, Zhuoxin;
    • Paietta, Elisabeth;
    • Tallman, Martin S.;
    • Cripe, Larry D.;
    • Atwater, Susan;
    • Appelbaum, Frederick R.
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17

    Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

    Published in:
    2005
    By:
    • Larson, Richard A;
    • Sievers, Eric L;
    • Stadtmauer, Edward A;
    • Löwenberg, Bob;
    • Estey, Elihu H;
    • Dombret, Hervé;
    • Theobald, Matthias;
    • Voliotis, Dimitris;
    • Bennett, John M;
    • Richie, Maria;
    • Leopold, Lance H;
    • Berger, Mark S;
    • Sherman, Matthew L;
    • Loken, Michael R;
    • van Dongen, Jacques J M;
    • Bernstein, Irwin D;
    • Appelbaum, Frederick R
    Publication type:
    journal article
    18

    Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence.

    Published in:
    Cancer (0008543X), 2005, v. 104, n. 7, p. 1442, doi. 10.1002/cncr.21326
    By:
    • Richard A. Larson;
    • Eric L. Sievers;
    • Edward A. Stadtmauer;
    • Bob Löwenberg;
    • Elihu H. Estey;
    • Hervé Dombret;
    • Matthias Theobald;
    • Dimitris Voliotis;
    • John M. Bennett;
    • Maria Richie;
    • Lance H. Leopold;
    • Mark S. Berger;
    • Matthew L. Sherman;
    • Michael R. Loken;
    • Jacques J. M. van Dongen;
    • Irwin D. Bernstein;
    • Frederick R. Appelbaum
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29

    Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

    Published in:
    Cancers, 2020, v. 12, n. 9, p. 2339, doi. 10.3390/cancers12092339
    By:
    • Morsink, Linde M.;
    • Sandmaier, Brenda M.;
    • Othus, Megan;
    • Palmieri, Raffaele;
    • Granot, Noa;
    • Bezerra, Evandro D.;
    • Wood, Brent L.;
    • Mielcarek, Marco;
    • Schoch, Gary;
    • Davis, Chris;
    • Flowers, Mary E. D.;
    • Deeg, H. Joachim;
    • Appelbaum, Frederick R.;
    • Storb, Rainer;
    • Walter, Roland B.
    Publication type:
    Article
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    Outpatient bendamustine and idarubicin for upfront therapy of elderly acute myeloid leukaemia/myelodysplastic syndrome: a phase I/II study using an innovative statistical design.

    Published in:
    British Journal of Haematology, 2014, v. 166, n. 3, p. 375, doi. 10.1111/bjh.12905
    By:
    • Lionberger, Jack M.;
    • Pagel, John M.;
    • Sandhu, Vicky K.;
    • Xie, Hu;
    • Shadman, Mazyar;
    • Mawad, Raya;
    • Boehm, Alexandra;
    • Dean, Carol;
    • Shannon‐Dorcy, Kathleen;
    • Scott, Bart L.;
    • Deeg, Hans Joachim;
    • Becker, Pamela S.;
    • Hendrie, Paul C.;
    • Walter, Roland B.;
    • Ostronoff, Fabiana;
    • Appelbaum, Frederick R.;
    • Estey, Elihu H.
    Publication type:
    Article
    41
    42

    Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.

    Published in:
    British Journal of Haematology, 2014, v. 165, n. 4, p. 497, doi. 10.1111/bjh.12775
    By:
    • Coutre, Steven E.;
    • Othus, Megan;
    • Powell, Bayard;
    • Willman, Cheryl L.;
    • Stock, Wendy;
    • Paietta, Elisabeth;
    • Levitan, Denise;
    • Wetzler, Meir;
    • Attar, Eyal C.;
    • Altman, Jessica K.;
    • Gore, Steven D.;
    • Maher, Tracy;
    • Kopecky, Kenneth J.;
    • Tallman, Martin S.;
    • Larson, Richard A.;
    • Appelbaum, Frederick R.
    Publication type:
    Article
    43
    44
    45

    Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2014, v. 164, n. 2, p. 223, doi. 10.1111/bjh.12618
    By:
    • Deininger, Michael W.;
    • Kopecky, Kenneth J.;
    • Radich, Jerald P.;
    • Kamel‐Reid, Suzanne;
    • Stock, Wendy;
    • Paietta, Elisabeth;
    • Emanuel, Peter D.;
    • Tallman, Martin;
    • Wadleigh, Martha;
    • Larson, Richard A.;
    • Lipton, Jeffrey H.;
    • Slovak, Marilyn L.;
    • Appelbaum, Frederick R.;
    • Druker, Brian J.
    Publication type:
    Article
    46

    A model for prediction of FLT3- ITD and NPM1 (without FLT3- ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2013, v. 163, n. 1, p. 130, doi. 10.1111/bjh.12450
    By:
    • Ostronoff, Fabiana;
    • Othus, Megan;
    • Kantarjian, Hagop M.;
    • Meshinchi, Soheil;
    • Ravandi, Farhad;
    • Hendrie, Paul C.;
    • Faderl, Stefan;
    • Becker, Pamela S.;
    • Cortes, Jorge E.;
    • Pagel, John M.;
    • Petersdorf, Stephen H.;
    • Godwin, John E.;
    • Willman, Cheryl L.;
    • Pierce, Sherry A.;
    • List, Alan F.;
    • Sandhu, Ravinder K.;
    • Walter, Roland B.;
    • Stirewalt, Derek L.;
    • Appelbaum, Frederick R.;
    • Estey, Elihu H.
    Publication type:
    Article
    47
    48

    Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2011, v. 155, n. 2, p. 182, doi. 10.1111/j.1365-2141.2011.08831.x
    By:
    • Becker, Pamela S.;
    • Kantarjian, Hagop M.;
    • Appelbaum, Frederick R.;
    • Petersdorf, Stephen H.;
    • Storer, Barry;
    • Pierce, Sherry;
    • Shan, Jianqin;
    • Hendrie, Paul C.;
    • Pagel, John M.;
    • Shustov, Andrei R.;
    • Stirewalt, Derek L.;
    • Faderl, Stephan;
    • Harrington, Elizabeth;
    • Estey, Elihu H.
    Publication type:
    Article
    49
    50

    Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.

    Published in:
    British Journal of Haematology, 2010, v. 148, n. 1, p. 48, doi. 10.1111/j.1365-2141.2009.07919.x
    By:
    • Chauncey, Thomas R.;
    • Gundacker, Holly;
    • Shadman, Mazyar;
    • List, Alan F.;
    • Dakhil, Shaker R.;
    • Erba, Harry P.;
    • Slovak, Marilyn L.;
    • I-Ming Chen;
    • Willman, Cheryl L.;
    • Kopecky, Kenneth J.;
    • Appelbaum, Frederick R.
    Publication type:
    Article